Trepulmix

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Download Risalah maklumat (PIL)
23-01-2023
Download Ciri produk (SPC)
23-01-2023
Download Laporan Penilaian Awam (PAR)
21-09-2023

Bahan aktif:

Treprostinil sodium

Boleh didapati daripada:

SciPharm Sàrl

Kod ATC:

B01AC21

INN (Nama Antarabangsa):

treprostinil

Kumpulan terapeutik:

Antithrombotic agents

Kawasan terapeutik:

Hypertension, Pulmonary

Tanda-tanda terapeutik:

Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.

Ringkasan produk:

Revision: 4

Status kebenaran:

Authorised

Tarikh kebenaran:

2020-04-03

Risalah maklumat

                                31
B.
PACKAGE LEAFLET
32
PACKAGE LEAFLET: INFORMATION FOR THE USER
TREPULMIX 1 MG/ML SOLUTION FOR INFUSION
TREPULMIX 2.5 MG/ML SOLUTION FOR INFUSION
TREPULMIX 5 MG/ML SOLUTION FOR INFUSION
TREPULMIX 10 MG/ML SOLUTION FOR INFUSION
treprostinil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trepulmix is and what it is used for
2.
What you need to know before you use Trepulmix
3.
How to use Trepulmix
4.
Possible side effects
5.
How to store Trepulmix
6.
Contents of the pack and other information
1.
WHAT TREPULMIX IS AND WHAT IT IS USED FOR
WHAT TREPULMIX IS
The active ingredient of Trepulmix is treprostinil.
Treprostinil belongs to a group of medicines which work in a similar
way to the naturally occurring
prostacyclins. Prostacyclins are hormone-like substances which reduce
blood pressure by relaxing
blood vessels, causing them to widen, which allows the blood to flow
more easily. Prostacyclins can
also have an influence in preventing blood from clotting.
WHAT TREPULMIX IS USED TO TREAT
Trepulmix is used for the treatment of adult patients with inoperable
chronic thromboembolic
pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after
surgical treatment (severity
classified WHO Functional Class (FC) III or IV), to improve exercise
capacity and symptoms of the
disease. Chronic thromboembolic pulmonary hypertension is a condition
where your blood pressure is
too high in the blood vessels between the heart and the lungs causing
shortness of breath, dizziness,
tiredness, fainting, palpitations or abnor
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trepulmix 1 mg/ml solution for infusion
Trepulmix 2.5 mg/ml solution for infusion
Trepulmix 5 mg/ml solution for infusion
Trepulmix 10 mg/ml solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trepulmix 1 mg/ml solution for infusion:
One ml of solution contains 1 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 10 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 36.8 mg (1.60 mmol) sodium.
Trepulmix 2.5 mg/ml solution for infusion:
One ml of solution contains 2.5 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 25 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 37.3 mg (1.62 mmol) sodium.
Trepulmix 5 mg/ml solution for infusion:
One ml of solution contains 5 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 50 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 39.1 mg (1.70 mmol) sodium.
Trepulmix 10 mg/ml solution for infusion:
One ml of solution contains 10 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 100 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 37.4 mg (1.63 mmol) sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for infusion.
Clear colourless to slightly yellow solution, free from visible
particles with a pH of 6.0 – 7.2 and an
osmolality between 253 and 284 mOsm/kg.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Trepulmix is indicated for the treatment of adult patients with WHO
Functional Class (FC) III or IV
and:
-
inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or
-
persistent or recurrent CTEPH after surgical treatment to improve
exercise capacity.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Trepulmix should be initiated and monitored only by
clinicians experienced in the

                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 23-01-2023
Ciri produk Ciri produk Bulgaria 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 21-09-2023
Risalah maklumat Risalah maklumat Sepanyol 23-01-2023
Ciri produk Ciri produk Sepanyol 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 21-09-2023
Risalah maklumat Risalah maklumat Czech 23-01-2023
Ciri produk Ciri produk Czech 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 21-09-2023
Risalah maklumat Risalah maklumat Denmark 23-01-2023
Ciri produk Ciri produk Denmark 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 21-09-2023
Risalah maklumat Risalah maklumat Jerman 23-01-2023
Ciri produk Ciri produk Jerman 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 21-09-2023
Risalah maklumat Risalah maklumat Estonia 23-01-2023
Ciri produk Ciri produk Estonia 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 21-09-2023
Risalah maklumat Risalah maklumat Greek 23-01-2023
Ciri produk Ciri produk Greek 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 21-09-2023
Risalah maklumat Risalah maklumat Perancis 23-01-2023
Ciri produk Ciri produk Perancis 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 21-09-2023
Risalah maklumat Risalah maklumat Itali 23-01-2023
Ciri produk Ciri produk Itali 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 21-09-2023
Risalah maklumat Risalah maklumat Latvia 23-01-2023
Ciri produk Ciri produk Latvia 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 21-09-2023
Risalah maklumat Risalah maklumat Lithuania 23-01-2023
Ciri produk Ciri produk Lithuania 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 21-09-2023
Risalah maklumat Risalah maklumat Hungary 23-01-2023
Ciri produk Ciri produk Hungary 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 21-09-2023
Risalah maklumat Risalah maklumat Malta 23-01-2023
Ciri produk Ciri produk Malta 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 21-09-2023
Risalah maklumat Risalah maklumat Belanda 23-01-2023
Ciri produk Ciri produk Belanda 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 21-09-2023
Risalah maklumat Risalah maklumat Poland 23-01-2023
Ciri produk Ciri produk Poland 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 21-09-2023
Risalah maklumat Risalah maklumat Portugis 23-01-2023
Ciri produk Ciri produk Portugis 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 21-09-2023
Risalah maklumat Risalah maklumat Romania 23-01-2023
Ciri produk Ciri produk Romania 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 21-09-2023
Risalah maklumat Risalah maklumat Slovak 23-01-2023
Ciri produk Ciri produk Slovak 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 21-09-2023
Risalah maklumat Risalah maklumat Slovenia 23-01-2023
Ciri produk Ciri produk Slovenia 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 21-09-2023
Risalah maklumat Risalah maklumat Finland 23-01-2023
Ciri produk Ciri produk Finland 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 21-09-2023
Risalah maklumat Risalah maklumat Sweden 23-01-2023
Ciri produk Ciri produk Sweden 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 21-09-2023
Risalah maklumat Risalah maklumat Norway 23-01-2023
Ciri produk Ciri produk Norway 23-01-2023
Risalah maklumat Risalah maklumat Iceland 23-01-2023
Ciri produk Ciri produk Iceland 23-01-2023
Risalah maklumat Risalah maklumat Croat 23-01-2023
Ciri produk Ciri produk Croat 23-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 21-09-2023

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen